NEOG NEOGEN CORP
In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 711377 · Fiscal year ends 05/31
Financial factors as of 2026-08-31 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY-0.3%
TTM net income YoY94.6%
TTM EPS YoY94.6%
Revenue 3-yr CAGR-1.3%
Net income 3-yr CAGR—
Margins
Gross margin47.4%
Operating margin-0.8%
Net margin-6.3%
FCF margin5.6%
EBITDA margin12.3%
Returns
ROE-2.7%
ROA-1.7%
ROIC (approx.)-0.2%
Asset turnover0.26x
Leverage & solvency
Liabilities / assets36.8%
Debt / equity0.74x
Current ratio3.90x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-1.52x
Accruals ratio-4.2%
Payout ratio—
Capex / revenue4.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2027Q12026-08-31 | 2026Q4*2026-05-31 | 2026Q32026-02-28 | 2026Q22025-11-30 | 2026Q12025-08-31 | 2025Q4*2025-05-31 | 2025Q32025-02-28 | 2025Q22024-11-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $222.80M | $225.30M | $211.20M | $224.69M | $209.20M | $225.46M | $220.98M | $231.26M |
| Cost of revenue | $117.30M | $117.50M | $112.20M | $118.01M | $114.20M | $132.60M | $110.70M | $117.93M |
| Gross profit | $105.50M | $107.80M | $99.00M | $106.68M | $95.00M | $92.90M | $110.30M | $113.33M |
| R&D expense | $6.50M | $4.90M | $3.80M | $4.56M | $5.10M | $6.30M | $4.50M | $5.11M |
| SG&A expense | $59.30M | $58.70M | $60.30M | $65.21M | $60.90M | $53.00M | $55.80M | $57.77M |
| Operating income | -$1.80M | $3.10M | -$3.30M | -$5.38M | -$16.10M | -$611.20M | $5.40M | -$457.48M |
| Pretax income | -$14.90M | -$12.10M | -$20.30M | -$20.36M | $43.80M | -$631.20M | -$9.70M | -$476.57M |
| Income tax | -$3.00M | -$800,000 | -$3.30M | -$4.44M | $7.50M | -$19.00M | $1.20M | -$20.29M |
| Net income | -$11.90M | -$11.30M | -$17.00M | -$15.92M | $36.30M | -$612.20M | -$10.90M | -$456.28M |
| EBITDA | $27.30M | $32.50M | $25.62M | $23.55M | $13.00M | -$580.90M | $34.77M | -$427.44M |
| EPS (basic) | -0.05 | — | -0.08 | -0.07 | 0.17 | — | -0.05 | -2.10 |
| EPS (diluted) | -0.05 | — | -0.08 | -0.07 | 0.17 | — | -0.05 | -2.10 |
| Weighted avg. shares (diluted) | 218.10M | — | 217.67M | 217.41M | 217.30M | — | 217.03M | 216.81M |
| Balance sheet | ||||||||
| Cash & equivalents | $172.00M | $185.50M | $159.90M | $145.34M | $138.80M | $129.00M | $127.70M | $140.23M |
| Short-term investments | — | — | — | — | — | $0 | $0 | $0 |
| Receivables | $136.20M | $146.80M | $137.10M | $132.00M | $138.46M | $153.40M | $160.07M | $164.09M |
| Inventory | $146.10M | $144.30M | $161.70M | $162.77M | $193.41M | $190.80M | $205.44M | $198.27M |
| Current assets | $582.50M | $604.60M | $590.00M | $574.58M | $524.06M | $576.90M | $551.71M | $570.45M |
| PP&E, net | $329.80M | $329.80M | $331.90M | $332.36M | $345.89M | $339.10M | $327.84M | $310.55M |
| Goodwill | $1.05B | $1.05B | $1.05B | $1.05B | $1.07B | $1.06B | $1.67B | $1.67B |
| Intangibles | $1.30B | $1.32B | $1.34B | $1.36B | $1.39B | $1.41B | $1.44B | $1.46B |
| Total assets | $3.30B | $3.35B | $3.36B | $3.36B | $3.38B | $3.44B | $4.04B | $4.05B |
| Current liabilities | $149.50M | $158.20M | $150.60M | $147.05M | $146.21M | $174.00M | $141.20M | $151.19M |
| Short-term debt | $780.00M | $800.00M | $800.00M | $800.00M | $800.00M | $19.30M | — | — |
| Long-term debt | $774.20M | $793.70M | $793.30M | $792.93M | $792.53M | $874.80M | $890.61M | $889.87M |
| Total debt | $1.55B | $1.59B | $1.59B | $1.59B | $1.59B | $894.10M | $890.61M | $889.87M |
| Total liabilities | $1.22B | $1.25B | $1.26B | $1.26B | $1.26B | $1.37B | $1.38B | $1.39B |
| Shareholders' equity | $2.09B | $2.09B | $2.10B | $2.10B | $2.12B | $2.07B | $2.66B | $2.67B |
| Net debt | $1.38B | $1.41B | $1.43B | $1.45B | $1.45B | $765.10M | $762.90M | $749.64M |
| Shares outstanding | 218.30M | 217.70M | 217.67M | 217.53M | 217.30M | 217.00M | 217.04M | 216.94M |
| Cash flow statement | ||||||||
| Operating cash flow | $12.90M | $30.20M | $22.70M | $19.44M | $10.80M | $16.40M | $19.36M | $40.25M |
| Capital expenditure | $8.20M | $4.00M | $11.63M | $11.67M | $24.00M | $16.10M | $32.87M | $17.16M |
| Free cash flow | $4.70M | $26.20M | $11.07M | $7.78M | -$13.20M | $300,000 | -$13.51M | $23.10M |
| Investing cash flow | -$8.20M | -$4.00M | -$11.56M | -$11.67M | $97.70M | -$15.90M | -$32.45M | -$17.16M |
| Financing cash flow | -$19.00M | -$300,000 | $744,000 | -$451,000 | -$99.40M | -$2.10M | $945,000 | -$1.41M |
| Depreciation & amortization | $29.10M | $29.40M | $28.92M | $28.93M | $29.10M | $30.30M | $29.37M | $30.05M |
| Stock-based compensation | $3.10M | $3.00M | $1.10M | $4.34M | $5.00M | $4.30M | $4.16M | $4.82M |
Free plan shows the latest 8 periods; Pro shows all 65 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.